Importer of Controlled Substances; Notice of Application, 35239-35240 [2011-14972]
Download as PDF
<![CDATA[
35239
Federal Register / Vol. 76, No. 116 / Thursday, June 16, 2011 / Notices
will pay a penalty of $102,000, and will
install air emission controls at its plant
to reduce its emissions of Volatile
Organic Compounds into the air.
The Department of Justice will receive
for a period of thirty (30) days from the
date of this publication comments
relating to the Consent Decree.
Comments should be addressed to the
Assistant Attorney General,
Environment and Natural Resources
Division, and either emailed to
pubcomment-ees.enrd@usdoj.gov or
mailed to P.O. Box 7611, U.S.
Department of Justice, Washington, DC
20044–7611, and should refer to either:
United States v. Industries Inc., Civil
Action No. 3:11–cv–00915, or D.J. Ref.
90–5–2–1–09881. The Consent Decree
may be examined at the Office of the
United States Attorney, District of
Connecticut, Connecticut Financial
Center, 157 Church St., 23d Floor, New
Haven, Connecticut, and at the United
States Environmental Protection
Agency, 5 Post Office Square, Suite 100,
Boston, Massachusetts 02109. During
the public comment period, the Consent
Decree may also be examined on the
following Department of Justice Web
site, https://www.usdoj.gov/enrd/
Consent_Decrees.html. A copy of the
Consent Decree may also be obtained by
mail from the Consent Decree Library,
P.O. Box 7611, U.S. Department of
Justice, Washington, DC 20044–7611 or
by faxing or e-mailing a request to Tonia
Fleetwood (tonia.fleetwood@usdoj.gov),
fax no. (202) 514–0097, phone
confirmation number (202) 514–1547. In
requesting a copy from the Consent
Decree Library, please enclose a check,
payable to the U.S. Treasury, in the
amount of $9.50 (25 cents per page
reproduction cost), or, if by email or fax,
forward a check in the applicable
amount to the Consent Decree Library at
the stated address.
Maureen Katz,
Assistant Chief, Environmental Enforcement
Section, Environment and Natural Resources
Division.
[FR Doc. 2011–14914 Filed 6–15–11; 8:45 am]
BILLING CODE 4410–15–P
DEPARTMENT OF JUSTICE
srobinson on DSK4SPTVN1PROD with NOTICES
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
VerDate Mar<15>2010
17:18 Jun 15, 2011
Jkt 223001
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on May 3,
2011, Boehringer Ingelheim Chemicals,
Inc., 2820 N. Normandy Drive,
Petersburg, Virginia 23805, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of
Phenylacetone (8501), a basic class of
controlled substance listed in schedule
II.
The company plans to import the
listed controlled substance to bulk
manufacture amphetamine.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration,
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43
and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than July 18, 2011.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
DEPARTMENT OF JUSTICE
Dated: June 7, 2011.
Joseph T. Rannazzisi
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Importer of Controlled Substances;
Notice of Application
[FR Doc. 2011–14976 Filed 6–15–11; 8:45 am]
BILLING CODE 4410–09–P
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
This is notice that on March 1, 2011,
Penick Corporation, 33 Industrial Park
Road, Pennsville, New Jersey 08070,
made application by renewal to the
Drug Enforcement Administration
(DEA) for registration as an importer of
the following basic classes of controlled
substances:
Drug
Coca Leaves (9040) .....................
Raw Opium (9600) .......................
Poppy Straw (9650) .....................
Concentrate of Poppy Straw
(9670).
Schedule
II
II
II
II
The company plans to import the
listed controlled substances to
manufacture bulk controlled substance
intermediates for sale to its customers.
As explained in the Correction to
Notice of Application pertaining to
Rhodes Technologies, 72 FR 3417
(2007), comments and requests for
hearings on applications to import
narcotic raw material are not
appropriate.
As noted in a previous notice
published in the Federal Register on
September 23, 1975, 40 FR 43745, all
applicants for registration to import a
basic class of any controlled substance
in schedule I or II are, and will continue
to be, required to demonstrate to the
Deputy Assistant Administrator, Office
of Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. § 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: June 7, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–14975 Filed 6–15–11; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
E:\FR\FM\16JNN1.SGM
16JNN1
35240
Federal Register / Vol. 76, No. 116 / Thursday, June 16, 2011 / Notices
srobinson on DSK4SPTVN1PROD with NOTICES
952(a) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on March
14, 2011, Noramco Inc., 1440 Olympic
Drive, Athens, Georgia 30601, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as an importer of
Phenylacetone (8501), a basic class of
controlled substance listed in schedule
II.
The company plans to import the
listed controlled substance in bulk for
the manufacture of a controlled
substance.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration,
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43,
and in such form as prescribed by
21 CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than July 18, 2011.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substance listed in
schedule I or II are, and will continue
to be, required to demonstrate to the
Deputy Assistant Administrator, Office
of Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to
21 U.S.C. 958(a); 21 U.S.C. 823(a); and
21 CFR 1301.34(b), (c), (d), (e), and (f)
are satisfied.
Dated: June 7, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–14972 Filed 6–15–11; 8:45 am]
BILLING CODE 4410–09–P
VerDate Mar<15>2010
17:18 Jun 15, 2011
Jkt 223001
DEPARTMENT OF JUSTICE
Drug
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on March
1, 2011, Lipomed, Inc., One Broadway,
Cambridge, Massachusetts 02142, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of the
following basic classes of controlled
substances:
Drug
Schedule
Cathinone (1235) ..........................
Methcathinone (1237) ..................
N-Ethylamphetamine (1475) ........
Fenethylline (1503) .......................
Methaqualone (2565) ...................
Gamma
Hydroxybutyric
Acid
(2010).
Lysergic acid diethylamide (7315)
2,5-Dimethoxy-4-(n)propylthiophenethylamine
(7348).
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Mescaline (7381) ..........................
3,4,5-Trimethoxyamphetamine
(7390).
4-Bromo-2,5dimethoxyamphetamine (7391).
4-Bromo-2,5dimethoxyphenethylamine
(7392).
4-Methyl-2,5dimethoxyamphetamine (7395).
2,5-Dimethoxyamphetamine
(7396).
2,5-Dimethoxy-4ethylamphetamine (7399).
3,4-Methylenedioxyamphetamine
(7400).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3,4Methylenedioxymethamphetamine (7405).
4-Methoxyamphetamine (7411) ...
Dimethyltryptamine (7435) ...........
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
N-Benzylpiperazine (7493) ...........
Acetyldihydrocodeine (9051) ........
Dihydromorphine (9145) ...............
Heroin (9200) ...............................
Normorphine (9313) .....................
Pholcodine (9314) ........................
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
Tilidine (9750) ...............................
3-Methylfentanyl (9813) ................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Methylphenidate (1724) ................
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
Phencyclidine (7471) ....................
Phenylacetone (8501) ..................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Benzoylecgonine (9180) ...............
Ethylmorphine (9190) ...................
Hydrocodone (9193) .....................
Levorphanol (9220) ......................
Meperidine (9230) ........................
Methadone (9250) ........................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Alfentanil (9737) ...........................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
Schedule
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to import
analytical reference standards for
distribution to its customers for research
and analytical purposes.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances may file comments or
objections to the issuance of the
proposed registration, and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43, and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than July 18, 2011.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
§ 1301.34(b), (c), (d), (e), and (f). As
noted in a previous notice published in
the Federal Register on September 23,
1975, 40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
E:\FR\FM\16JNN1.SGM
16JNN1
]]>Agencies
[Federal Register Volume 76, Number 116 (Thursday, June 16, 2011)]
[Notices]
[Pages 35239-35240]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-14972]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to
issuing a registration under this Section to a bulk manufacturer of a
controlled substance in schedule I or II, and prior to issuing a
regulation under 21 U.S.C.
[[Page 35240]]
952(a) authorizing the importation of such a substance, provide
manufacturers holding registrations for the bulk manufacture of the
substance an opportunity for a hearing.
Therefore, in accordance with 21 CFR 1301.34(a), this is notice
that on March 14, 2011, Noramco Inc., 1440 Olympic Drive, Athens,
Georgia 30601, made application by letter to the Drug Enforcement
Administration (DEA) to be registered as an importer of Phenylacetone
(8501), a basic class of controlled substance listed in schedule II.
The company plans to import the listed controlled substance in bulk
for the manufacture of a controlled substance.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic class of controlled
substance may file comments or objections to the issuance of the
proposed registration, and may, at the same time, file a written
request for a hearing on such application pursuant to 21 CFR 1301.43,
and in such form as prescribed by 21 CFR 1316.47.
Any such comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than July 18, 2011.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR 1301.34(b), (c),
(d), (e), and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975, 40 FR 43745-46, all applicants
for registration to import a basic class of any controlled substance
listed in schedule I or II are, and will continue to be, required to
demonstrate to the Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration, that the requirements for
such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and
21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: June 7, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2011-14972 Filed 6-15-11; 8:45 am]
BILLING CODE 4410-09-P
